ダウンロード数: 219
このアイテムのファイル:
| ファイル | 記述 | サイズ | フォーマット | |
|---|---|---|---|---|
| 29_0105.pdf | 426.77 kB | Adobe PDF | 見る/開く |
| タイトル: | 前立腺再燃癌Stage Dに対するTegafurの長期投与効果について |
| その他のタイトル: | Effects of long-term administration of Tegafur on patients with relapsing advanced carcinoma (stage D) of the prostate |
| 著者: | 吉田, 謙一郎  根岸, 壮治 小林, 信幸 斉藤, 隆 大和田, 文雄 安島, 純一 佐竹, 一郎 田利, 清信 |
| 著者名の別形: | Yoshida, Kenichiro Negishi, Takeharu Kobayashi, Nobuyuki Saito, Takashi Owada, Fumio Ajima, Jun-ichi Satake, Ichiro Tari, Kiyonobu |
| キーワード: | Aged Estrogens/administration & dosage Fluorouracil/analogs & derivatives Follow-Up Studies Humans Male Middle Aged Neoplasm Recurrence, Local Neoplasm Staging Prostatic Neoplasms/drug therapy/pathology Tegafur/administration & dosage |
| 発行日: | Jan-1983 |
| 出版者: | 泌尿器科紀要刊行会 |
| 誌名: | 泌尿器科紀要 |
| 巻: | 29 |
| 号: | 1 |
| 開始ページ: | 105 |
| 終了ページ: | 111 |
| 抄録: | Daily 600 mg of Tegafur, in addition to antiandrogen therapy, was administered to 20 patients with relapsing prostatic carcinoma at stage D. Thirteen of the patients died and 7 patients are still alive. These patients were evaluated according to the objective response criteria of NPCP . Three patients showed partial regression, 9 patients showed stable prognosis and 8 patients showed progression. The patients who died had a mean survival duration of 77 weeks, which is longer than in other reports on the treatment of relapsing prostatic carcinoma. No severe toxicity was observed in any of the patients. These findings suggest that Tegafur is effective for the treatment of relapsing prostatic carcinoma. |
| URI: | http://hdl.handle.net/2433/120093 |
| PubMed ID: | 6428191 |
| 出現コレクション: | Vol.29 No.1 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。